Dr. Hani Salti, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 225 N Milwaukee Ave, Vernon Hills, IL 60061 Phone: 847-941-7970 |
Dr. Tara Atta, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 225 N Milwaukee Ave, Vernon Hills, IL 60061 Phone: 847-444-5300 |
News Archive
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX in the EU, announced today that it has injected the first patient in its placebo-controlled Phase 2 clinical trial of CCH for the treatment of lipoma.
The Washington Post reports on the Republican battle plan, which will undoubtedly include Obama's past claims about lowering the cost of insurance premiums. The Associated Press reports on how the GOP primary race has yet to "fully test" candidate Mitt Romney's health care record. Also, The Hill reports that the Republican presidential field appears to be "moving to the right" on abortion issues.
Scientists and physicians at UC San Francisco (UCSF) are leading a $26 million, multi-institutional research program in which they will employ advanced technology to characterize human brain networks and better understand and treat a range of common, debilitating psychiatric disorders, focusing first on anxiety disorders and major depression.
The likelihood of treatment success of 48 wk peg-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic hepatitis C may be predicted by viral kinetics on therapy. In particular, recent studies have shown that sustained virological response (SVR) can be predicted by a rapid virological response (RVR), and an early virological response (EVR).
› Verified 9 days ago